<SEC-DOCUMENT>0001493152-20-009957.txt : 20200527
<SEC-HEADER>0001493152-20-009957.hdr.sgml : 20200527
<ACCEPTANCE-DATETIME>20200527180152
ACCESSION NUMBER:		0001493152-20-009957
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20200522
FILED AS OF DATE:		20200527
DATE AS OF CHANGE:		20200527

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Kruger Kurt H
		CENTRAL INDEX KEY:			0001375881

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37428
		FILM NUMBER:		20916457

	MAIL ADDRESS:	
		STREET 1:		100 FOXBOROUGH BLVD
		STREET 2:		SUITE 240
		CITY:			FOXBOROUGH
		STATE:			MA
		ZIP:			02035

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Qualigen Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001460702
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				263474527
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		1880 CENTURY PARK EAST, SUITE 1000
		CITY:			LOS ANGELES
		STATE:			CA
		ZIP:			90067
		BUSINESS PHONE:		310-203-1000

	MAIL ADDRESS:	
		STREET 1:		1880 CENTURY PARK EAST, SUITE 1000
		CITY:			LOS ANGELES
		STATE:			CA
		ZIP:			90067

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	RITTER PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20090402
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>ownership.xml
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0306</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2020-05-22</periodOfReport>

    <notSubjectToSection16>0</notSubjectToSection16>

    <issuer>
        <issuerCik>0001460702</issuerCik>
        <issuerName>Qualigen Therapeutics, Inc.</issuerName>
        <issuerTradingSymbol>QLGN</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001375881</rptOwnerCik>
            <rptOwnerName>Kruger Kurt H</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O QUALIGEN THERAPEUTICS, INC.,</rptOwnerStreet1>
            <rptOwnerStreet2>2042 CORTE DEL NOGAL</rptOwnerStreet2>
            <rptOwnerCity>CARLSBAD</rptOwnerCity>
            <rptOwnerState>CA</rptOwnerState>
            <rptOwnerZipCode>92011</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>1</isDirector>
            <isOfficer>0</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
            <officerTitle></officerTitle>
            <otherText></otherText>
        </reportingOwnerRelationship>
    </reportingOwner>

    <derivativeTable>
        <derivativeTransaction>
            <securityTitle>
                <value>Warrant (Right to Buy)</value>
                <footnoteId id="F1"/>
                <footnoteId id="F2"/>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>2.5405</value>
            </conversionOrExercisePrice>
            <transactionDate>
                <value>2020-05-22</value>
            </transactionDate>
            <deemedExecutionDate></deemedExecutionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>J</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionTimeliness></transactionTimeliness>
            <transactionAmounts>
                <transactionShares>
                    <value>8857</value>
                </transactionShares>
                <transactionPricePerShare>
                    <footnoteId id="F2"/>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <exerciseDate>
                <value>2020-05-22</value>
            </exerciseDate>
            <expirationDate>
                <value>2027-06-26</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>8857</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>8857</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeTransaction>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">On May 22, 2020, a reverse merger transaction between the Issuer and Qualigen, Inc. (&quot;Qualigen&quot;) was consummated such that Qualigen became a wholly-owned subsidiary of the Issuer (the &quot;Merger&quot;). Pursuant to and effective as of the closing of the Merger (the &quot;Closing&quot;), the Reporting Person became a director of the Issuer.</footnote>
        <footnote id="F2">Immediately prior to the Closing, the Reporting Person held Qualigen Series C convertible preferred stock warrants. Pursuant to the Merger, the Qualigen Series C convertible preferred stock warrants previously held by the Reporting Person were assumed by the Issuer and may be exercised solely for shares of common stock of the Issuer.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>/s/ Hayden Trubitt, Attorney-in-Fact for Kurt H. Kruger</signatureName>
        <signatureDate>2020-05-27</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
